In the recent outcome analysis of the phase 3 clinical PERFECT trial we are investigating intramyocardial transplantation of c-KIT/CD117+/CD133+,/CD34+ bone marrow derived hematopoeitic stem cells (BM-HSC) in post-myocardial infarction (MI) coronary artery bypass graft (CABG) patients. This evidence concerns the gene KIT and myocardial infarction.